HAVN Life Enters Distribution Agreement With Mycrodose Therapeutics For U.S. Market
HAVN Life Enters Distribution Agreement With Mycrodose Therapeutics For U.S. Market
HAVN Life Sciences Inc. (CSE:HAVN) (OTC:HAVLF) (FSE: 5NP), a biotechnology company working with psychedelic compounds for investigational research to support brain health and cognitive function, announced on Thursday its entry into an exclusive U.S. Distribution Agreement with California-based Mycrodose Therapeutics Inc., a leading pharmaceutical company specializing in the research and development of advanced drug delivery systems utilizing DEA Schedule I, II and III substances and other compounds aimed at treating cancer-related conditions, mental health, and cognitive degenerative diseases.
HAVN生命科学公司。(CSE：HAVN)(场外交易代码：HAVLF)(FSE：5NP)是一家生物技术公司，致力于研究迷幻化合物以支持大脑健康和认知功能，该公司周四宣布与总部位于加利福尼亚州的公司签订独家美国分销协议麦克罗剂量治疗公司。是一家领先的制药公司，专门研究和开发先进的药物输送系统，利用DEA附表I、II和III物质和其他化合物，旨在治疗癌症相关疾病、精神健康和认知退行性疾病。
The agreement will facilitate the import of HAVN Life's naturally derived GMP psilocybin to research institutions and researchers within the U.S. "at competitive prices" to alleviate "supply chain issues," reported HAVN in a press release.
HAVN在一份新闻稿中报道，这项协议将促进HAVN Life天然提取的GMP裸盖菇素“以具有竞争力的价格”进口到美国境内的研究机构和研究人员，以缓解“供应链问题”。
"HAVN Life is kicking off 2022 with strong partnerships in both our research and retail divisions, and we are very excited to start fulfilling purchase orders for our research customers with our new U.S. distribution partner, Mycrodose Therapeutics," said HAVN Life CEO, Tim Moore. "We've been working closely with Chad and his team, and are excited about the potential of this partnership."
HAVN Life首席执行官说：“2022年伊始，HAVN Life在我们的研究和零售部门都建立了强有力的合作伙伴关系，我们非常高兴能与我们新的美国分销合作伙伴Mycroose Treeutics一起为我们的研究客户完成采购订单，”HAVN Life首席执行官说：“HAVN Life在我们的研究和零售部门都有强大的合作伙伴关系。蒂姆·摩尔。“我们一直在与乍得和他的团队密切合作，并对这种伙伴关系的潜力感到兴奋。”
In December 2021, Mycrodose added a Schedule I Import license, which allows the import of psilocybin and psilocin for clinical trials, research and development, analytical purposes and distribution.
2021年12月，麦克罗糖增加了附表一进口许可证，允许进口裸盖菇素和裸盖菇素用于临床试验、研发、分析目的和分销。
"Our company's proven ability to navigate the meticulous details required for approval by the DEA and FDA for these very difficult licenses has directly contributed to Mycrodose's ability to lead the U.S.-Pharmaceutical sector," stated Chad Conner, CEO of Mycrodose Therapeutics. "This distribution partnership with HAVN Life increases access and the ease of obtaining GMP psilocybin for any U.S.-based research institution, university, or private biotech company."
他说：“我们公司被证明有能力驾驭DEA和FDA批准这些非常困难的许可证所需的细致细节，这直接促成了麦克罗糖领导美国制药行业的能力。”查德·康纳麦克罗剂量治疗公司的首席执行官。与HAVN Life的这一经销伙伴关系增加了任何总部设在美国的研究机构、大学或私营生物技术公司获得GMP裸盖菇素的机会和便利性。“
According to HVN, "the interest and demand for psilocybin research in the United States have grown significantly in 2021 and continue to outpace supply in 2022."
据HVN报道，“美国对裸盖菇素研究的兴趣和需求在2021年大幅增长，并在2022年继续超过供应。”
The firm noted that the DEA Increased the quota for psilocybin research in the U.S. Meanwhile HAVN and Mycrodose, have completed the first purchase order and delivery of naturally derived GMP raw psilocybin mushrooms from Jamaica into the United States.
该公司指出，DEA增加了美国裸盖菇素研究的配额。与此同时，HAVN和Mycrodde已经完成了从牙买加向美国运送天然GMP生裸盖菌素蘑菇的第一笔订单和交货。
Image By Ilona Szentivanyi.
图片由Ilona Szentivanyi拍摄。
译文内容由第三方软件翻译。